# A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

> **NCT04494243** · PHASE1 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 40 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** AD-214 10/600mg
- **DRUG:** Rabeprazole 10mg

## Key facts

- **NCT ID:** NCT04494243
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-28
- **Primary completion:** 2021-01-15
- **Final completion:** 2021-01-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494243, "A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04494243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*